• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Science & Medicine / Cancer / Private-Public Partnerships in Cancer Vaccine Research

Private-Public Partnerships in Cancer Vaccine Research

February 14, 2011 By admin Leave a Comment

By Aleea Farrakh, originally published in “Benchmarks” June 2008

Even though the National Cancer Institute is the leading Federal government agency for cancer research, it is hardly the sole contributor in the fight against cancer. Other government agencies, non-profit organizations, academia and private industry all play critical roles in helping find a cure for the disease. The combined efforts of many groups can result in productive partnerships where different organizations can, collectively and individually, play significant roles in achieving progress.

Benchmarks sat down with Philip Arlen, M.D., director of the Clinical Research Group in the Laboratory of Tumor Immunology and Biology, part of NCI’s Center for Cancer Research, to discuss his views on partnerships related to vaccine development.

Benchmarks -What are some examples of major successes in public/private partnerships when it comes to vaccine development?

Dr. Philip Arlen: There are therapeutic vaccines and preventative vaccines– a good example for preventative vaccines is the work of Drs. Douglas Lowy and John Schiller here at NCI which has led to the development of the HPV vaccine that is being utilized not only in the U.S., but all over the world commercially. Currently, no therapeutic [treatment] vaccine has been approved by the FDA. However, a couple of examples of partnerships resulting with private industry and NCI/academia include:

– The PSA-TRICOM vaccine was developed at NCI, and initially involved a partnership with Therion Biologics. [This partnership] resulted in a number of promising Phase II studies with the vaccine in prostate cancer. A CRADA [Cooperative Research and Development Agreement] to work with the NCI and Bavarian Nordic (BN) ImmunoTherapeutics Inc., to further develop this vaccine is now ongoing.

– A partnership with Globeimmune Inc. and the NCI through a CRADA has resulted in a Saccharomyces-CEA based vaccine that is leading to an IND [Investigational New Drug] and Phase I study at the NCI.

– Johns Hopkins University (an NCI-funded institution) has worked extensively with CellGenesys in developing whole-cell tumor vaccines secreting GM-CSF (a protein that stimulates immune cell growth).

Benchmarks: What are the major barriers when working with private industry?

Learn the answer this and many more questions…….

(Note from SaneVax:  It behooves every medical consumer in the world to gain an understanding of how so-called public [government] – private [corporate] partnerships work, especially when it comes to vaccine research and development. Basically, in the case of HPV vaccines, the government did the initial research and then turned the information over [retaining a financial interest] to pharmacuetical companies for them to conduct the clinical trials, manufacture and market any vaccines developed from the initial government research. All in the effort to get vaccines to the market quicker.

The SaneVax Team wants to know who is watching out for the medical consumer? How can government agencies fulfill their role as guardians of health and safety when they have a financial interest in the product being brought to market?

 

Related

Filed Under: Cancer, NCI, Vaccine Science Tagged With: cancer research, NCI, public private partnerships, vaccine development

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Ana from Cantabria

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Gardasil Cervarix HPV Vaccine Survey

Have you or your child been given a genetically modified vaccine?

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in